Dergiler / Turkish Neurosurgery / 2016 / Cilt: 26 - Sayı: 4

Prognostic Value of Angiogenesis and Survivin Expression in Patients with Glioblastoma

Sayfa
484–490
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Since only malignant cells express survivin, it might be a target protein for the development of novel therapies.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:AIM: Glioblastoma (GBM) is the most common and the most aggressive primary brain tumor with poor prognosis.
📊
Temel Bulgular & Veri:Control tissues were obtained from the archive for each antibody (Survivin, CD 34).
💡
Sonuç & Katkı:Since only malignant cells express survivin, it might be a target protein for the development of novel therapies.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

AIM: Glioblastoma (GBM) is the most common and the most aggressive primary brain tumor with poor prognosis. We aimed to evaluate the association between immunohistochemical expression of survivin and angiogenic parameters (microvessel density and vascular pattern) in patients who underwent surgery for GBM. MATERIAL and METHODS: The pathology reports and also clinical and follow-up data of patients with GBM were retrospectively evaluated. Control tissues were obtained from the archive for each antibody (Survivin, CD 34). Then, control staining of these antibodies was performed. Vessels were evaluated according to the standardized assessment of vascular pattern. RESULTS: Mean survival for classical vascular pattern was longer than bizarre vascular pattern (p<0.001). The survival time of patients decreased with increasing score of survivin staining. There was a significant correlation between survivin and survival time (p<0.001). There was no significant correlation between microvessel density and survival time (p>0.05). CONCLUSION: With these findings, it is considered that high expression of survivin, bizarre vascular pattern and development of secondary GBM correlates with the low survival rates, however microvessel density has no correlation with the survival rates. Since only malignant cells express survivin, it might be a target protein for the development of novel therapies.

🔖

Bu Makaleye Atıf Yap

TAŞTEKİN, E., ÇALOĞLU, V. Y., PUYAN, F. Ö., TOKUÇ, B., ÇALOĞLU, H. M., YALTA, T. D., CAN, N., GÜLER, B. (2016). Prognostic Value of Angiogenesis and Survivin Expression in Patients with Glioblastoma. Turkish Neurosurgery, Cilt: 26 - Sayı: 4, 484–490. https://ajindex.com/articles/404665

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152(1):43-49, 1998 2. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8(1):61-70, 2008 3. Benitez JA, Dominguez-Monzon G, Segovia J: Conventional and gene therapy strategies for the treatment of brain tumors. Curr Med Chem 15(8):729-742, 2008 4. Bernsen HJJA, Rijken PF, Hagemeier NE, van der Kogel AJ: A quantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites. Microvasc Res 57(3):244-257, 1999 5. Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rossler K, Budka H, Harris AL, Hainfellner JA: Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypes. Brain Pathol 13(2):133-143, 2003 6. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20(4):1063-1068, 2002 7. Drappatz J, Norden AD, Wen PY: Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 9(4):519-534, 2009 8. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1):4-6, 1990 9. Hansen S, Grabau DA, Rose C, Bak M, Sorensen FB: Angiogenesis in breast cancer: A comparative study of the observer variability of methods for determining microvessel density. Lab Invest 78(12):1563-1573, 1998 10. Henson JW: Treatment of glioblastoma multiforme: A new standard. Arch Neurol 63(3):337-341, 2006 11. Jiao BH, Yao ZG, Geng SM, Zuo SH: Expression of survivin, a novel apoptosis inhibitor and cell cycle regulatory protein, in human gliomas. Chin Med J (Engl) 117(4):612-614, 2004 12. Kanwar JR, Kamalapuram SK, Kanwar RK: Targeting survivin in cancer: Patent review. Expert Opin Ther Pat 20(12):1723- 1737, 2010 13. Kanwar RK, Cheung CH, Chang JY, Kanwar JR: Recent advances in anti-survivin treatments for cancer. Curr Med Chem 17(15):1509-1515, 2010 14. Khasraw M, Lassman AB: Advances in the treatment of malignant gliomas. Curr Oncol Rep 12(1):26-33, 2010 15. Lakka SS, Rao JS: Antiangiogenic therapy in brain tumors. Expert Rev Neurother 8(10):1457-1473, 200